文献速递妇科

子宫内膜异位症女性中枢敏化的患病率及危险因素

Prevalence and Risk Factors of Central Sensitization in Women with Endometriosis.
PubMed 文献 · J Minim Invasive Gynecol · 2022-10-29

单中心观察性横断面研究纳入2022年1月15日至4月30日转诊的285例子宫内膜异位症患者,用中枢敏化量表(评分≥40)评估中枢敏化,患病率为41.4%(95%CI 35.8-47.2)。多变量分析显示中枢敏化与中重度慢性盆腔痛、后外侧宫旁受累、激素治疗失败、偏头痛或紧张型头痛、肠易激综合征、焦虑或惊恐发作显著相关。

要点

  • 子宫内膜异位症患者中枢敏化患病率为41.4%(95%CI 35.8-47.2)。
  • 多变量分析显示中枢敏化与中重度慢性盆腔痛、后外侧宫旁受累、激素治疗失败显著相关。
  • 偏头痛或紧张型头痛、肠易激综合征、焦虑或惊恐发作也与中枢敏化显著相关。

核心结论

  • 子宫内膜异位症患者中枢敏化患病率高,尤其见于中重度慢性盆腔痛、后外侧宫旁受累、激素治疗失败及3种中枢敏感综合征(偏头痛或紧张型头痛、肠易激综合征、焦虑或惊恐发作)者。
  • 鉴于与激素治疗失败的关联,通过中枢敏化量表识别中枢敏化可能有助于咨询患者并选择多模式治疗。

研究设计与样本

  • 单中心、观察性、横断面研究,连续纳入2022年1月15日至2022年4月30日转诊至三级中心的子宫内膜异位症患者285例。
  • 使用中枢敏化量表问卷(评分≥40)评估中枢敏化,采用贝叶斯Jeffreys法计算患病率95%CI,用卡方检验和Fisher精确检验评估关联,再行多变量logistic回归,显著性水平设为0.05。

主要发现

  • 中枢敏化患病率为41.4%(95%CI 35.8-47.2)。
  • 单变量分析中,不孕、中重度疼痛症状(排便痛除外)、排便改变、后外侧宫旁受累、激素治疗失败及大多数中枢敏感综合征与中枢敏化发生显著相关。
  • 多变量分析仅证实中枢敏化与中重度慢性盆腔痛、后外侧宫旁受累、激素治疗失败、偏头痛或紧张型头痛、肠易激综合征、焦虑或惊恐发作显著相关。

临床怎么用

  • 作者认为,鉴于中枢敏化与激素治疗失败的关联,通过中枢敏化量表识别中枢敏化可能有助于咨询患者并选择多模式治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To assess prevalence of central sensitization (CS) and its association with demographic and clinical factors in patients with endometriosis. DESIGN: Single-center, observational, cross-sectional study. SETTING: Tertiary center. PATIENTS: Consecutive patients with endometriosis referred to the center from January 15, 2022, to April 30, 2022. INTERVENTIONS: For each enrolled patient, demographic and clinical data were collected, and the presence of CS was measured using the CS Inventory questionnaire (score ≥40). MEASUREMENTS AND MAIN RESULTS: Primary study outcome was CS prevalence, and secondary study outcomes were the associations between demographic and clinical factors and CS. The 95% confidence intervals for CS prevalence were obtained with Bayesian-derived Jeffreys method, and the associations between CS and demographic and clinical factors were evaluated with the chi-square test and Fisher's exact test, where appropriate. The variables significantly associated with CS were then included in a multivariable logistic regression model. The significance level was set at .05 for all analyses. During the study period, 285 eligible women were enrolled. CS prevalence was 41.4% (95% confidence interval, 35.8-47.2). At univariable analysis, infertility, moderate to severe pain symptoms (except for dyschezia), altered bowel movements, posterolateral parametrium involvement, hormonal therapy failure (HTF), and most of central sensitivity syndromes were significantly associated with CS occurrence. Multivariable analysis only confirmed the significant association of CS with moderate to severe chronic pelvic pain, posterolateral parametrium involvement, HTF, migraine or tension-type headache, irritable bowel syndrome, and anxiety or panic attacks. CONCLUSION: CS has a high prevalence in patients with endometriosis, especially in those with moderate to severe chronic pelvic pain, posterolateral parametrium involvement, HTF, and 3 central sensitivity syndromes (i.e. migraine or tension-type headache, irritable bowel syndrome, anxiety or panic attacks). Given the association with HTF, identifying CS through CS Inventory might be useful to counsel the patient and to choose multimodal treatment.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Raimondo D, Raffone A, Renzulli F, et al. Prevalence and Risk Factors of Central Sensitization in Women with Endometriosis. J Minim Invasive Gynecol. 2022. PMID: 36441085. doi:10.1016/j.jmig.2022.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。